合并其他神经免疫抗体的抗髓鞘少突胶质细胞糖蛋白抗体相关疾病  

Myelin oligodendrocyte glycoprotein antibody-associated disease combined with other neuroimmune antibodies

作　　者：钟晓南[1] 王霞 邱伟[1] 胡学强[1] 陆正齐[1] Zhong Xiaonan;Wang Xia;Qiu Wei;Hu Xueqiang;Lu Zhengqi(Department of Neurology,the Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630,China;Department of Neurology,Huizhou Sixth People's Hospital,Huizhou 516211,China)

机构地区：[1]中山大学附属第三医院神经内科,广州510630 [2]惠州市第六人民医院神经内科,惠州516211

出　　处：《中华神经科杂志》2025年第2期204-209,共6页Chinese Journal of Neurology

基　　金：广东省自然科学基金(2022A1515012398);国家自然科学基金(82071344)。

摘　　要：抗髓鞘少突胶质细胞糖蛋白(MOG)-IgG虽然是抗MOG抗体相关疾病(MOGAD)诊断的生物学标志物,但MOG-IgG本身在疾病诊断的特异性仍然存在一些争议。临床上,MOG-IgG低滴度MOGAD患者临床异质性显著,低滴度的MOG-IgG甚至可以在无症状人群中被检测到。同时,MOG-IgG阳性者常合并多种其他神经系统自身免疫抗体阳性。因此,MOG-IgG与MOGAD的关系错综复杂,MOGAD的发病机制可能存在MOG-IgG以外的免疫因素参与。文中综述合并其他神经免疫抗体的MOGAD的研究进展,为将来临床医师对这类疾病的早期识别和治疗提供帮助。Although myelin oligodendrocyte glycoprotein(MOG)-IgG is a biological marker for diagnosing MOG antibody-associated disease(MOGAD),the specificity of MOG-IgG in disease diagnosis remains controversial.In clinical practice,there is significant heterogeneity in MOGAD patients with low titer of MOG-IgG and low titer MOG-IgG can even be detected in asymptomatic populations.At the same time,MoG-IgG-positive individuals often combine with the positivity of other multiple autoimmune antibodies in the nervous system.Therefore,the relationship between MOG-IgG and MOGAD is complex,and the pathogenesis of MOGAD may involve immune factors other than MOG-IgG.This article reviews the research progress of MOGAD combined with other neuroimmune antibodies,assisting in the early identification and treatment of such diseases by clinical physicians in the future.

关 键 词：髓鞘少突胶质细胞糖蛋白 免疫球蛋白G 抗体相关疾病 生物学标记 双阳性 

分 类 号：R741[医药卫生—神经病学与精神病学]